In this study, we report the synthesis and evaluation of in vitro and in vivo antitrypanosomal
activity of styrylquinoline-like compounds (SQ) 3a-h. Synthesis was carried out by using …

Objectives There is an urgent need to develop a safe, effective, orally active, and
inexpensive therapy for African trypanosomiasis due to the drawbacks of current drugs …

The current treatment of Chagas disease is based on the use of two drugs, nifurtimox (Nfx)
and benznidazole (Bnz), both of which present limited efficacy in the chronic stage of the …

A series of quinone derivatives with a variety of side chains were synthesized. These
synthetic quinone compounds were evaluated for in vitro antitrypanosomal activity against …

Human African trypanosomiasis is caused by a protozoan parasite Trypanosoma brucei
majorly infecting people living in sub-Saharan Africa. Current limited available treatments …

Pyrazole and propenone quinoxaline derivatives were tested against intracellular forms of
Leishmania peruviana and Trypanosoma cruzi. Both series were tested for toxicity against …

The discovery and development of essential drugs for Chagas disease is a major concern
worldwide. New substituted 1, 4-naphthoquinones were synthesized and tested against the …

Chagas disease, caused by the protozoan Trypanosoma cruzi, is a neglected chronic
tropical infection endemic in Latin America. New and effective treatments are urgently …

To develop novel chemotherapeutic alternatives for the treatment of Chagas disease, in this
study, a set of new amino naphthoquinone derivatives were synthesised and evaluated in …

Trypanosomiasis remains a major threat to humans in sub-Saharan Africa with 55-60 million
people in 36 countries at risk of infection with Tb gambiense or Tb rhodesiense. Only a few …